Create Free Account

By creating account you will get access to hot stocks & personalised emails

CSL Ltd

Healthcare AU CSL

279.61AUD
-2.4(0.85%)

Last update at 2024-12-11T05:10:00Z

Day Range

278.08281.43
LowHigh

52 Week Range

260.63311.28
LowHigh

Fundamentals

  • Previous Close 282.01
  • Market Cap137098.38M
  • Volume550233
  • P/E Ratio33.71
  • Dividend Yield1.40%
  • EBITDA4618.00M
  • Revenue TTM14800.00M
  • Revenue Per Share TTM30.64
  • Gross Profit TTM 6844.00M
  • Diluted EPS TTM8.40

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 2663.00M 2779.60M 2963.10M 2572.70M 2341.10M
Minority interest -50.00000M - - - -
Net income 2194.00M 2254.70M 2375.00M 2102.50M 2102.50M
Selling general administrative 1086.00M 688.00M 731.70M 691.80M 574.80M
Selling and marketing expenses 1454.00M 960.70M 980.20M 896.20M 866.80M
Gross profit 6708.00M 5663.50M 5798.60M 5176.10M 4748.70M
Reconciled depreciation 831.00M 542.50M 495.30M 610.96M 536.03M
Ebit 3071.00M 2922.40M 3198.18M 2723.50M 2517.80M
Ebitda 3902.00M 3464.90M 3629.20M 3143.30M 2893.20M
Depreciation and amortization 831.00M 542.50M 431.02M 419.80M 375.40M
Non operating income net other - - - - -
Operating income 4884.05M 4239.47M 4174.17M 3936.21M 2517.80M
Other operating expenses 3989.22M 2951.84M 2322.20M 2037.44M 6410.00M
Interest expense 408.00M 142.80M 170.80M 150.80M 176.70M
Tax provision 419.00M 524.90M 588.10M 470.20M 422.40M
Interest income 406.00M 17.40M 3.90M 143.80M 162.90M
Net interest income -406.00000M -160.60000M -166.90000M -219.72898M -232.28290M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 419.00M 524.90M 588.10M 470.20M 422.40M
Total revenue 13174.00M 10493.10M 10265.30M 9100.50M 8509.90M
Total operating expenses 4606.00M 3347.40M 3208.60M 2929.70M 2648.80M
Cost of revenue 6466.00M 4829.60M 4466.70M 3924.40M 3761.20M
Total other income expense net 136.00M 81.60M 44.70M 50.30M -176.70000M
Discontinued operations - - - - -
Net income from continuing ops 2244.00M 2254.70M 2375.00M 3063.53M 2735.92M
Net income applicable to common shares 2194.00M 2254.70M 2375.00M 2102.50M 1918.70M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 56931.95M 36234.00M 28346.00M 18156.90M 15464.60M
Intangible assets 8267.00M 8367.00M 1450.80M 1481.60M 986.00M
Earning assets - - - - -
Other current assets 568.99M 9.00M 4.20M 231.80M 180.80M
Total liab 27882.01M 18408.00M 13768.50M 9775.60M 8937.20M
Total stockholder equity 25998.35M 15786.00M 14577.50M 8381.30M 6527.40M
Deferred long term liab - - - - -
Other current liab 4436.62M 5687.30M 9437.77M 49.70M 3.20M
Common stock 557.00M 517.00M 483.80M 483.80M -4561.00000M
Capital stock 557.00M 517.00M 483.80M -4504.60000M -4561.00000M
Retained earnings 23975.44M 14621.00M 13503.40M 12252.70M 10752.10M
Other liab - 2628.00M 1496.50M 1338.90M 1005.20M
Good will 12097.03M 8079.00M 1187.30M 1188.10M 1154.20M
Other assets 0.00000M 908.00M 938.60M 540.00M 558.60M
Cash 2481.10M 1548.00M 10436.40M 1808.80M 1194.40M
Cash and equivalents - - - - -
Total current liabilities 7411.84M 4608.00M 7108.20M 3103.60M 2141.50M
Current deferred revenue 263.53M -2954.30320M -7415.37440M 2057.10M 1477.70M
Net debt 15761.02M 10679.00M -778.60000M 3998.10M 4798.40M
Short term debt 1413.49M 1055.00M 4494.00M 473.80M 202.30M
Short long term debt 848.00M 964.00M 4420.50M 396.00M 180.68M
Short long term debt total 18242.12M 12227.00M 9657.80M 5806.90M 5992.80M
Other stockholder equity -557.00000M -29492.00020M -26783.81280M -16340.20072M -15580.08270M
Property plant equipment - 9352.00M 8308.60M 7536.00M 6305.40M
Total current assets 16123.38M 9259.00M 16460.70M 7389.70M 6446.20M
Long term investments 163.00M 173.00M 402.90M 21.50M 20.69M
Net tangible assets - -660.00000M 11939.40M 5711.60M 4387.20M
Short term investments - 9.00M 4.20M 4.80M 3.30M
Net receivables 4143.15M 1905.00M 1483.20M 1563.70M 1558.20M
Long term debt 9671.00M 9564.00M 3862.50M 4228.50M 4824.60M
Inventory 8930.15M 5466.00M 4333.00M 3780.60M 3509.50M
Accounts payable 1298.20M 820.00M 591.80M 523.00M 458.30M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2022.91M 648.00M 590.30M 633.20M 336.30M
Additional paid in capital - - - - -
Common stock total equity - - - - -6645.78173M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 8156.51M 102.00M 18.20M 10.50M 15.60M
Deferred long term asset charges - - - - -
Non current assets total 40808.56M 26975.00M 11885.30M 10767.20M 9018.40M
Capital lease obligations 1664.00M 1699.00M 1374.80M 1182.40M 124.44M
Long term debt total - 11172.00M 5163.80M 5333.10M 4831.70M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -11843.00000M -387.70000M -1673.20000M -1991.40318M -1835.59105M
Change to liabilities 197.00M 212.30M 454.90M 157.80M 136.20M
Total cashflows from investing activities -11843.00000M -1636.10000M -1673.20000M -1366.70000M -1287.30000M
Net borrowings 1661.00M 3723.70M -496.70000M 198.80M 288.30M
Total cash from financing activities 456.00M 7675.90M -1401.80000M -642.70000M -491.50000M
Change to operating activities 51.00M -102.70000M 56.40M -27.00000M 18.60M
Net income 3294.07M 3266.14M 3167.30M 3046.52M 1918.70M
Change in cash -8825.00000M 8604.30M 578.80M 493.50M -154.90000M
Begin period cash flow 10334.00M 1730.10M 1151.30M 657.80M 812.70M
End period cash flow 1509.00M 10334.40M 1730.10M 1151.30M 657.80M
Total cash from operating activities 3905.14M 3807.84M 4830.17M 3605.55M 1644.40M
Issuance of capital stock 34.00M 4988.40M 56.40M 42.00M 31.80M
Depreciation 1088.52M 647.43M 533.84M 508.60M 375.40M
Other cashflows from investing activities -10151.00000M -0.70000M -6.10000M 18.70M -2.50000M
Dividends paid 1239.00M 1038.70M 958.00M 883.10M 806.80M
Change to inventory -1361.76980M -1306.45680M -490.36472M -993.14460M -558.30000M
Change to account receivables 42.04M -65.17800M 48.68M 191.12M -367.10000M
Sale purchase of stock 2539.00M 4092.70M 38.70M 1652.70M 898.50M
Other cashflows from financing activities -80.00000M -50.10000M -68.00000M -55.10000M -4.80000M
Change to netincome 207.00M 668.80M 571.50M -11.50000M 120.80M
Capital expenditures 1692.00M 1247.70M 1667.10M 1367.60M 1284.80M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1319.73060M -1371.63480M -441.68832M -802.02150M 1644.40M
Stock based compensation 208.69M 169.46M 122.42M 117.37M -
Other non cash items -477.44520M -105.73320M 1129.03M 50.43M -2294.10000M
Free cash flow 2213.14M 2560.14M 3163.07M 2237.95M 359.60M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CSL
CSL Ltd		 -2.4 0.85% 279.61 33.71 33.56 9.22 5.16 6.82 21.15
TLX
Telix Pharmaceuticals Ltd		 -0.32 1.31% 24.15 166.27 21.01 12.93 20.38 12.77 111.52
MSB
Mesoblast Ltd		 -0.07 4.12% 1.63 - 454.55 323.07 2.86 67.90 -9.8623
CU6
Clarity Pharmaceuticals Ltd		 -0.32 5.83% 5.17 - - 156.12 12.91 - -0.7791
NEU
Neuren Pharmaceuticals Ltd		 0.47 3.62% 13.44 13.72 15.22 8.58 5.17 6.53 8.52

Reports Covered

Stock Research & News

View All

Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

CSL Ltd

655 Elizabeth Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Paul R. Perreault B.A. MD, CEO & Exec. Director 1957
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI Chief Financial Officer 1965
Dr. Paul F. McKenzie Ph.D. Chief Operating Officer 1966
Mr. Mark Dehring Head of Investor Relations NA
Mr. Gregory Boss B.S., BS(Hons), J.D. Exec. VP of Legal & Group Gen. Counsel 1961
Christina Hickie Sr. Mang. of Communications NA
Ms. Elizabeth Walker B.A., M.S. Exec. VP & Chief HR Officer 1970
Dr. Karen Etchberger Exec. VP of Quality & Bus. Services 1958
Dr. Wilfried Freudenberg Department Head of Albumin & Immunoglobulins Production NA
Ms. Jemimah Brennan Head of Communications - Asia Pacific NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.